News from creabilis sa

Jul 29, 2013, 04:57 ET

Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board

Creabilis SA, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces that it has appointed Professor...

May 10, 2013, 03:00 ET

Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327

Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European...

Apr 23, 2013, 06:39 ET

Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE 'Topical-by-Design' Technology

Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, for inflammation...

Feb 28, 2013, 04:37 ET

Creabilis Appoints Catherine Moukheibir to its Board of Directors

Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, inflammation and...

Nov 05, 2012, 04:47 ET

Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award

£1.42m Funding Will Drive Development of New Treatment for Atopic Dermatitis Creabilis SA, a European biotechnology company specialising in...

May 03, 2012, 04:00 ET

Creabilis Appoints Dr Simon Russell as Chief Business Officer

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, announces...

Feb 29, 2012, 04:00 ET

Creabilis Announces Start of Phase IIb Trial of TrkA Kinase Inhibitor CT327 in Psoriasis

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today...

Oct 04, 2011, 03:00 ET

Creabilis Raises €15M ($20M) in Series B Fundraising Round

Funds to Advance Development of Creabilis' First-in-Class Products Creabilis SA, a clinical stage European biotechnology company addressing unmet...

Aug 18, 2011, 04:00 ET

Creabilis Expands Senior Management Team

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announced...

Aug 04, 2011, 05:12 ET

Creabilis Appoints Dr David Roblin as Chief Medical Officer

  Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain,...

Mar 10, 2011, 03:59 ET

Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from...

Dec 15, 2010, 04:25 ET

Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in...

Sep 29, 2010, 04:28 ET

Creabilis Appoints Dr. Eliot Forster as its New Chief Executive Officer

Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today...

Sep 15, 2010, 03:59 ET

Creabilis Appoints George F. Horner III as its Chairman

Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge